AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04634942 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryos REF 0971 Cold Spray
Description: Cold Spray Coolant spray is manufactured from liquefied gases with high pressure. It acts by rapidly reducing the temperature in the body area where it is applied. The liquefied gas in the tube spreads on the skin in liquid form and takes the heat of the skin by turning into gas. The temperature of the area where it is applied drops from 30-32 degrees to 10-15 degrees. With the effect of the cold, the excitability of the nerve endings decreases, and thus the pain on the skin is felt by the person. Cold sprays, whose analgesic effect occurs immediately, are applied parallel to the muscle fibers in the area to be applied, from a distance of 15-45 centimeters, by squeezing for approximately 5-15 seconds. Cold sprays are suitable for long-term and multiple uses.
Study NCT04634942 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Cryos REF 0971 Cold Spray
Description: Cold Spray Coolant spray is manufactured from liquefied gases with high pressure. It acts by rapidly reducing the temperature in the body area where it is applied. The liquefied gas in the tube spreads on the skin in liquid form and takes the heat of the skin by turning into gas. The temperature of the area where it is applied drops from 30-32 degrees to 10-15 degrees. With the effect of the cold, the excitability of the nerve endings decreases, and thus the pain on the skin is felt by the person. Cold sprays, whose analgesic effect occurs immediately, are applied parallel to the muscle fibers in the area to be applied, from a distance of 15-45 centimeters, by squeezing for approximately 5-15 seconds. Cold sprays are suitable for long-term and multiple uses.
Study NCT04634942 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ShotBlocker BIONIX Press Firmly USA
Description: ShotBlocker ShotBlocker is a plastic tool with a small and flat shape, with short and non-sharp protrusions on one side that connect with the skin. It resembles a horseshoe (C shaped) with its structure designed to expose the area to be injected. It is suitable for all age groups. It does not have any side effects. ShotBlocker can be used for both intramuscular and subcutaneous injections. The protruding surface of the ShotBlocker is held by pressing the skin during the injection and the process is performed from the part where the opening is.
Study NCT04634942 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ShotBlocker BIONIX Press Firmly USA
Description: ShotBlocker ShotBlocker is a plastic tool with a small and flat shape, with short and non-sharp protrusions on one side that connect with the skin. It resembles a horseshoe (C shaped) with its structure designed to expose the area to be injected. It is suitable for all age groups. It does not have any side effects. ShotBlocker can be used for both intramuscular and subcutaneous injections. The protruding surface of the ShotBlocker is held by pressing the skin during the injection and the process is performed from the part where the opening is.
Study NCT03583736 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual visit
Description: Virtual visit with oncologist following uterine cancer diagnosis prior to scheduled office visit.
Study NCT03583736 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Office visit
Description: Scheduled office visit with oncologist following uterine cancer diagnosis.
Study NCT02372422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound determination of cervical length
Description: Transvaginal ultrasound was used to measure the length of the cervix from the internal to external os relying on a standard approach and clinicians caring for the patients were made aware of the results.
Study NCT02372422 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Routine care
Description: Routine prenatal care of twins. Digital exams were permitted, but transvaginal ultrasound assessment of cervical length was not.
Study NCT01059383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VECAM 40/300
Description: 1 capsule, orally, once daily at bedtime.
Study NCT01059383 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 20 mg
Description: 1 capsule, orally, once daily 30-60 min. before dinner
Study NCT02830620 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dosage of chimiokines
Study NCT00516035 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca)
Description: Vaccine given by nasal spray
Study NCT02332824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan cilexetil
Description: Candesartan cilexetil tablets
Study NCT03044184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Transamine is an antifibrinolytic medication given systemically via the intravenous route
Study NCT03230292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Bimekizumab will be administered subcutaneously in 2 different doses.
Study NCT03529279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNG Chemotherapy
Description: CNG I, IMRT plus oral adjuvant chemotherapy, if EBV-DNA > 0,according to CNG II. CNG II, IMRT + concurrent chemotherapy + oral adjuvant chemotherapy. CNG III, systemic chemotherapy, plus IMRT.~Chemotherapy strategy: Concurrent chemotherapy, 5-Fu + nedaplatin (cisplatin), every 28 days; 5-Fu 500mg/m2. D, civ d1-d5, nedaplatin (cisplatin) 80mg (70mg) /m2. D, D1. Systemic chemotherapy, 5-Fu + nedaplatin (cisplatin), every 60 days; 5-Fu (100 - 200 mg/m2. D) civ for 30 days, nedaplatin (cisplatin) 80mg (70mg) /m2. D, D1,D28. Aim to achieve CR in imaging.Oral adjuvant chemotherapy, tegafon (400 mg, QID) and Calcium Folinate Tablets (30 mg, QID). Oral 10 days and stop 20 days, 3 months/course. After 6 courses, oral 10 days and stop 50 days, half year/course, 6-7 courses, lasted for 5 years.
Study NCT03529279 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NCCN Chemotherapy
Description: UICC I, IMRT. UICC II-IVA, concurrent chemoradiotherapy ± adjuvant chemotherapy, or induced chemotherapy plus concurrent chemoradiotherapy. UICC IVB, platinum based combined chemotherapy, followed by IMRT or concurrent chemoradiotherapy, or concurrent chemoradiotherapy.~Chemotherapy strategy: Concurrent cisplatin with or without cisplatin plus 5-Fu or carboplatin combined with 5-Fu adjuvant chemotherapy; The combined chemotherapy regimen of IVB stage patients may choose cisplatin or carboplatin plus docetaxel or paclitaxel, cisplatin plus 5-Fu, carboplatin and cetuximab, cisplatin plus gemcitabine, and gemcitabine. The combination of vinorelbine and cisplatin, carboplatin, paclitaxel, docetaxel, 5-Fu, methotrexate, gemcitabine and capecitabine can be used in combination with radiotherapy.
Study NCT03529279 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CNG Radiation
Description: IMRT technique. GTV was given to 6810cGy, CTV1 was given to 6000cGy, and CTV2 was given to 4800-5400cGy. 30 fractions, daily, QW1-5.~CT-SIM or MR-CIM was evaluated every 10 fractions. If CR for CNG I and II patients at 10 fractions, radiotherapy were given 25 fractions, that was, GTV was given to 5675cGy, CTV1 was given 5000cGy, and CTV2 was given 4000-4500cGy, 25 fractions, daily, QW1-5.~If tumor reduced less than 50% at 20 fractions, GTV was modified according to tumor size at 20 fractions. The modified GTV was given 300cGy/F×5 after 25 fractions; the original CTV1 and CTV2 were unchanged, that is, GTV was given to 5675cGy/25Fr+1500cGy/5Fr and CTV1 was given to 6000cGy/30Fr, CTV2 was given 4800-5400cGy/30Fr.
Study NCT03529279 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: NCCN Radiation
Description: IMRT technique. When IMRT alone, GTV were given (1) 66Gy (2.2Gy/Fr) to 70-70.2 Gy (1.8-2.0 Gy/Fr), QW1-5, 6-7 weeks; (2) 69.96 Gy (2.12 Gy/Fr), 6-7 weeks; CTV1-2 were given 44-50 (2.0 Gy/Fr) to 54-63 (1.8 Gy/Fr).~When combined with chemotherapy, GTV were given 70-70.2 Gy (1.8-2.0 Gy/Fr), QW1-5, 7 weeks; CTV1-2 were given 44-50 Gy (2 Gy/Fr) to 54-63 Gy (1.8 Gy/Fr).~When palliative radiotherapy, 50Gy/20Fr; 37.5 Gy/15Fr (if tolerable, increases 5 fractions to 50Gy); 30Gy/10Fr, 30Gy/5Fr, 2 fractions per week, interval more than 3 days; 44.4Gy/12Fr was divided into 3 cycles, 2 fractions a day, 6 hours of interval, 2 consecutive days and 3-4 weeks between two cycles. After second cycles, the treatment plan must completely avoid the irradiation of the spinal cord.
Study NCT00490620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination antiviral therapy
Description: Zidovudine 300mg and lamivudine 150mg BID for 6 months
Study NCT00490620 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo BID for 6 months
Study NCT00820872 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Study NCT00820872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT02332824 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Candesartan cilexetil Placebo
Description: Candesartan cilexetil placebo-matching tablets
Study NCT02332824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil Placebo
Description: Candesartan cilexetil placebo-matching tablets
Study NCT00820872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study NCT01526265 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will receive reimbursements for completing the surveys that are part of the Way To Quit program and for submitting saliva or urine samples at 14 days, 30 days, 6 months, and 12 months (among those eligible).
Study NCT01526265 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Rewards
Description: If participants quit smoking by their target quit date, and that is confirmed by cotinine/anabasine tests, they will receive a monetary award from the study investigators.
Study NCT01526265 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fixed Deposits
Description: Participants will have to deposit a certain monetary amount of their own money as an incentive to quit smoking. If they quit smoking by their target quit date, and that is confirmed by cotinine/anabasine tests, participants will receive their deposit back. If participants do not quit, their money will be used to support future research studies designed to help people stop smoking. As a motivation to quit smoking, the participant's deposit will be matched by the study investigators in a rate of 3:1.
Study NCT01526265 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Competitive Deposits (Pari-Mutuel)
Description: Groups (or cohorts) of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day 0's) near each other. Participants will deposit a certain monetary amount (Y) in an account, which will be matched on a rate of 3:1 by the study investigators (M), and the payout for quitting on this arm will be (Y+M) x 6/Q , where Q is the number of quits in the cohort. Again, success will be confirmed by cotinine or anabasine tests, and if participants do not quit, their money will be used to support future research studies designed to help people stop smoking.
Study NCT01526265 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Rewards
Description: Groups (or cohorts) of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day 0's) near each other. If participants quit smoking by their target quit date, and that is confirmed by cotinine or anabasine tests, they will receive a monetary award from the study investigators. On top of that, participants will receive an additional monetary amount for each member of their group who also quits smoking. These participants will interact through a chat room, which will help motivate them to quit smoking.
Study NCT03676322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5049
Description: Participants will receive single ascending oral dose of M5049 in Part A. Participants will receive multiple ascending oral dose of M5049 once daily for 14 days or twice daily for 13 days followed by a single dose on Day 14 in the morning in Part B. Participants will receive a single oral dose of M5049 under fed conditions in Part C.
Study NCT03676322 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matched to M5049.
Study NCT03406806 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SprintSystem device
Description: The walking path will be set according to the directions of the NIH toolbox 4 meter clinic walk test which includes marking the beginning and end of the walking path. A standard manual stopwatch will be used to record time. The examiner will demonstrate the task then instruct the participant to Walk at a comfortable pace and count down by saying: 3, 2, 1, go. The stop watch will be used to time the amount of time it takes to walk between the cones. Subjects will complete 3 timed trials. The time will be recorded in the log. Simultaneously, the Sprint System \[6\] will be operated according to manufacturers instructions. The Gaitbox will be set up at the end of the 4 meter walking path at a height of 4 feet from the floor. Times/speeds will be recorded on log sheet.
Study NCT03406806 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NIH toolbox 4 meter walk
Description: The walking path will be set according to the directions of the NIH toolbox 4 meter clinic walk test which includes marking the beginning and end of the walking path. A standard manual stopwatch will be used to record time. The examiner will demonstrate the task then instruct the participant to Walk at a comfortable pace and count down by saying: 3, 2, 1, go. The stop watch will be used to time the amount of time it takes to walk between the cones. Subjects will complete 3 timed trials. The time will be recorded in the log. Simultaneously, the Sprint System \[6\] will be operated according to manufacturers instructions. The Gaitbox will be set up at the end of the 4 meter walking path at a height of 4 feet from the floor. Times/speeds will be recorded on log sheet.
Study NCT01342627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib will be orally administered at a daily dose of 400 mg taken twice daily without food, at least one hour before or two hours after eating. Four weeks of treatments will be considered as a cycle. Each patient enrolled in the study will received medications for topical therapy. Dermatological medications will be provided free.~In case of toxicities, dose reduction/interruption is permitted according to the protocol.~In case of disease progression Sorafenib administration will be discontinued.
Study NCT04749797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Used as cranial block for craniotomy surgery
Study NCT04749797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Injection
Description: Used as cranial block for craniotomy surgery
Study NCT04749797 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Used as cranial block for craniotomy surgery
Study NCT00828178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3
Description: Omega-3-acid ethyl esters (Lovaza) 3 gram once a day for 12 weeks
Study NCT03740373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGF MDI (budesonide, glycopyrronium and formoterol fumarate) with 10 s breath hold
Description: Participants will receive a single dose of BGF MDI; the dose will be administered with a 10 s breath-hold.
Study NCT03740373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGF MDI ((budesonide, glycopyrronium and formoterol fumarate) with 3 s breath hold
Description: Participants will receive a single dose of BGF MDI; the dose will be administered with a 3 s breath-hold.
Study NCT02477631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone
Description: This is a single-arm, open-label, multi-center study in 20 patients with MDS. All participants will be treated with deferiprone for up to 4 months.
Study NCT02452034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole IV solution
Description: Posaconazole by IV solution twice on Day 1, then once daily on Days 2-10.
Study NCT00828178 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: flow-mediated dilation of the brachial artery
Description: flow-mediated dilation of the brachial artery measurement at baseline and after 12 weeks
Study NCT00828178 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: flow-mediated dilation of the brachial artery
Description: flow-mediated dilation of the brachial artery measurement at baseline and after 12 weeks
Study NCT00828178 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: corn starch
Description: 3 capsules qd for 12weeks
Study NCT00632736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropinirole XL (formerly CR)
Study NCT01790100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-135
Description: 12 weeks of VX-135
Study NCT00820872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Study NCT01790100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 12 weeks of ribavirin
Study NCT02919059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Description: Dagliflozin will be administred once daily before the first meal of the day for the duration of the study or until early discontinuation. Subjects will take the first dose of study drug at the study centre on Day 1.~On the day of study visits when fasting blood samples are collected, subjects will be instructed to refrain from taking the study drug before the clinic visit. The subject will be instructed to take the dose of study drug before the subject´s next meal.~The study drug must be swallowed whole with liquid and not chewed, divided, dissolved or crushed. If the subject doesn´t take the study drug within 12 hours after the first meal of the day, the dose of the study drug should be skipped for that day and keep on taking the study drug on the following day before the first meal.
Study NCT02919059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride 4 mg
Description: Glimepiride will be administred once daily before the first meal of the day for the duration of the study or until early discontinuation. Subjects will take the first dose of study drug at the study centre on Day 1.~On the day of study visits when fasting blood samples are collected, subjects will be instructed to refrain from taking the study drug before the clinic visit. The subject will be instructed to take the dose of study drug before the subject´s next meal.~The study drug must be swallowed whole with liquid and not chewed, divided, dissolved or crushed. If the subject doesn´t take the study drug within 12 hours after the first meal of the day, the dose of the study drug should be skipped for that day and keep on taking the study drug on the following day before the first meal.
Study NCT02909244 — intervention group
Intervention type: BIOLOGICAL
Intervention: Biological sampling
Description: Biological sampling
Study NCT03183856 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Morning walk
Description: a end-effector typed gait robot with a saddle
Study NCT03183856 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: no Morning walk
Description: ambulation voluntary or with a help of walker
Study NCT02944981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Single oral dose
Study NCT02944981 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oral dose
Study NCT00296309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Immunosuppression
Study NCT02452034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole powder for oral suspension
Description: Posaconazole once daily by PFS for a minimum of 10 days
Study NCT00296309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Immunosuppression
Study NCT00321672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGX-4010, 8% capsaicin patch
Description: Up to 4 NGX-4010 patches of 280 cm\^2 each were applied to the feet (2 per foot) for 60 minutes.
Study NCT00321672 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 0.04% capsaicin patch
Description: Up to 4 control patches of 280 cm\^2 each were applied to the feet (2 per foot) for 60 minutes.
Study NCT00321672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGX-4010, 8% capsaicin patch
Description: Up to 4 NGX-4010 patches of 280 cm\^2 each were applied to the feet (2 per foot) for 30 minutes.
Study NCT00321672 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 0.04% capsaicin patch
Description: Up to 4 control patches of 280 cm\^2 each were applied to the feet (2 per foot) for 30 minutes.
Study NCT01670526 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rivastigmine Transdermal Patch
Description: Cholinesterase Inhibitor
Study NCT01670526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine Transdermal Patch
Description: Cholinesterase Inhibitor
Study NCT01667159 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Cognitive Behavioral Therapy
Description: Individual CBT sessions for parents and adolescents plus combined parent-adolescent family sessions delivered at least 1-2x each week for 6 months.